@FiercePharma: Tuesday's best-read new news: Teva braces for $550M hit from Copaxone generics. Story | Follow @FiercePharma
@EricPFierce: The here and now of track and trace. Editor's corner | Follow @EricPFierce
@CarlyHFierce: Tuesday's most popular special report: Top 10 generics makers by 2012 revenue. Report | Follow @CarlyHFierce
> The Brazilian drugmaker and consumer goods manufacturer Hypermarcas plans to sell off some of its drug-manufacturing rights and other assets to Merck's ($MRK) Brazilian unit. Report
> Sanofi ($SNY) plans to sell its Paris life sciences park to the public investment group Caisse de Depots in a two-stage deal to be wrapped up by 2015. Report
> Israel Corp. Chairman Amir Elstein will step down at the end of the year to join Teva Pharmaceutical Industries' ($TEVA) board as vice chair. Report
> Zogenix ($ZGNX) won FDA approval for a new 4 mg dose of its Sumavel migraine and cluster headache injection. Release
> Popular stomach-acid drugs known as proton-pump inhibitors are linked with an increased risk of vitamin B12 deficiency, which can lead to a variety of other health problems. Report (sub. req.)
> Endo Health Solutions ($ENDP) tapped Arthur Higgins to join its board of directors, while Joseph Scodari will retire from the board. Release
@FierceMedDev: Echo Therapeutics finds a China partner for its glucose monitor, satisfies an angry investor. Article | Follow @FierceMedDev
@MarkHFierce: Presenting, our latest issue of FierceDiagnostics--check it out, and tell a friend. Issue | Follow @MarkHFierce
@MichaelGFierce: Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. More from FierceDrugDelivery | Follow @MichaelGFierce
@GalenMoore: Imploding microbubbles give transdermal patch an edge over arthritis. Story | Follow @GalenMoore
> Ireland resists tougher EU device regulations. More
> LabCorp predicts another 'difficult' year in 2014 as revenues lag. Article
> After losing a $27M judgment to St. Jude Medical, AccessClosure touts a win. News
Biotech News
@FierceBiotech: Big Biopharmas help fuel $26M round for Sutro's antibody R&D work. News | Follow @FierceBiotech
@JohnCFierce: GEN ranks VCs by total funds under management. Hmmmm. Feature via GEN | Follow @JohnCFierce
@DamianFierce: With fresh hopes and a bunch of new safety data, Orexigen is going back to the FDA with Contrave. Story | Follow @DamianFierce
@EmilyMFierce: 1 in 100 cancers are associated with a particular gene mutation, according to a Sanger Institute study. Story from FierceBiotech Research | Follow @EmilyMFierce
> Avanir hits the skids after its pain drug flunks a mid-stage study. More
> Celgene chips in $20M to extend Agios cancer deal. Story
Diagnostics News
> French company unveils prenatal test based on licensed Sequenom tech. Story
> DioGenix's venture round fuels expanded trial for MS molecular Dx test. Report
> New Hologic CEO pledges to grow, and not sell, the women's health Dx company. More
> Foundation Medicine shows test's worth as a highly specific blood cancer screening tool. Article
> Invitae's $40M Series E adds rocket fuel to genetic test expansion plans. News
> Sequenta expands reach of ultrasensitive cancer Dx test. Item
Biomarkers News
> Biomarker points to aggressive breast cancer in black women. Story
> Cellular switch biomarker predicts prostate cancer's spread. Piece
> In China, lung cancer biomarker testing is on the rise. More
> Gene biomarker may determine whether some depression drugs will work. News
> New tech promises to speed up biomarker validation. Article
> Inflammatory marker presents a new target for obesity drug developers. Item
Drug Delivery News
> Alliqua CEO: Celgene deal vaults us to 'another level of respectability'. Article
> Protein 'crossing guard' carries Alzheimer's drug past the blood-brain barrier. More
> Imploding microbubbles give transdermal patch an edge for arthritis drugs. News
> Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill. Report
> Rutgers team delivers RNA to weaken drug-resistant ovarian cancer. Story
> Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment. Item
And Finally… A former Pfizer ($PFE) factory in Flushing, NY, has traded medicine for chocolate. Report